Fundamental Analysis of PROMETHEUS BIOSCIENCES INC(NASDAQ:RXDX) stock

Fundamental Rating

RXDX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While RXDX has a great health rating, there are worries on its profitability. RXDX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

RXDX had negative earnings in the past year.

In the past year RXDX has reported a negative cash flow from operations.

In the past 5 years RXDX always reported negative net income.

RXDX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The profitability ratios for RXDX are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RXDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.

RXDX has more shares outstanding than it did 1 year ago.

RXDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 94.07 indicates that RXDX is not in any danger for bankruptcy at the moment.

RXDX has a better Altman-Z score (94.07) than 99.20% of its industry peers.

There is no outstanding debt for RXDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	94.07

ROIC/WACCN/A

WACC8.62%

2.3 Liquidity

RXDX has a Current Ratio of 37.56. This indicates that RXDX is financially healthy and has no problem in meeting its short term obligations.

RXDX has a Current ratio of 37.56. This is amongst the best in the industry. RXDX outperforms 98.56% of its industry peers.

RXDX has a Quick Ratio of 37.56. This indicates that RXDX is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 37.56, RXDX belongs to the best of the industry, outperforming 98.56% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	37.56
Quick Ratio	37.56

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RXDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.62%.

Looking at the last year, RXDX shows a very negative growth in Revenue. The Revenue has decreased by -36.47% in the last year.

RXDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 82.51% yearly.

EPS 1Y (TTM)-26.62%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-4.88%

Revenue 1Y (TTM)-36.47%

Revenue growth 3Y82.51%

Revenue growth 5YN/A

Revenue growth Q2Q-71.8%

3.2 Future

Based on estimates for the next years, RXDX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.32% on average per year.

The Revenue is expected to grow by 145.93% on average over the next years. This is a very strong growth

EPS Next Y-16.9%

EPS Next 2Y-15.66%

EPS Next 3Y-15.77%

EPS Next 5Y22.32%

Revenue Next Year-69.44%

Revenue Next 2Y-47.62%

Revenue Next 3Y136.24%

Revenue Next 5Y145.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXDX. In the last year negative earnings were reported.

Also next year RXDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as RXDX's earnings are expected to decrease with -15.77% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-15.66%

EPS Next 3Y-15.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RXDX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROMETHEUS BIOSCIENCES INC

NASDAQ:RXDX (6/15/2023, 7:23:19 PM)

After market: 199.95 +0.03 (+0.02%)

199.92

+0.18 (+0.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap9.56B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	37.56
Quick Ratio	37.56
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-26.62%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-16.9%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-36.47%

Revenue growth 3Y82.51%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROMETHEUS BIOSCIENCES INC (RXDX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens